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ABSTRACT
Introduction Individuals recruited into clinical trials for 
life- threatening illnesses are particularly vulnerable. This 
is especially true in low- income settings. The decision 
to enrol may be influenced by existing inequalities, poor 
healthcare infrastructure and fear of death. Where patients 
are confused or unconscious the responsibility for this 
decision falls to relatives. This qualitative study is nested 
in the ongoing AMBIsome Therapy Induction OptimisatioN 
(AMBITION) Trial. AMBITION is recruiting participants from 
five countries in sub- Saharan Africa and is trialling a 
novel treatment approach for HIV- associated cryptococcal 
meningitis, an infection known to affect brain function. We 
aim to learn from the experiences of participants, relatives 
and researchers involved in AMBITION.
Methods and analysis We will collect data through 
in- depth interviews with trial participants and the next 
of kin of participants who were confused at enrolment 
and therefore provided surrogate consent. Data will be 
collected in Gaborone, Botswana; Kampala, Uganda and 
Harare, Zimbabwe. Interviews will follow a narrative 
approach including participatory drawing of participation 
timelines. This will be supplemented by direct observation 
of the research process at each of the three recruiting 
hospitals. Interviews will also take place with researchers 
from the African and European institutions that form 
the partnership through which the trial is administered. 
Interviews will be transcribed verbatim, translated (if 
necessary) and organised thematically for narrative 
analysis.
Ethics and dissemination This study has been approved 
by the Health Research Development Committee, 
Gaborone (Reference: HPDME:13/18/1); Makerere School 
of Health Sciences Institutional Review Board, Kampala 
(Reference: 2019–061); University of Zimbabwe Joint 
Research Ethics Committee, Harare (Reference: 219/19), 
and the London School of Hygiene and Tropical Medicine 
(Reference: 17957). Study findings will be shared with 
research participants from the sites, key stakeholders 
at each research institution and ministries of health to 
help inform the development and implementation of 
future trials. The findings of this study will be published in 
journals and presented at academic meetings.
Trial registration Registered at www. clinicaltrials. gov: 
NCT04296292.
INTRODUCTION
Since the start of the HIV epidemic our knowl-
edge and understanding of the epidemiology 
and management of HIV and its numerous 
complications has exponentially increased. 
This knowledge has been produced through 
Strengths and limitations of this study
 ► There has been no previous qualitative study con-
ducted in a low- income setting which has aimed 
to explore the experience of individuals who enrol 
into a clinical trial for the management of a life- 
threatening illness.
 ► We plan to collect data from trial participants, their 
next of kin and researchers working on a multisite 
clinical trial and by doing this we can elicit a broad 
range of perspectives and experiences that can in-
form the improvement of this and similar trials in 
the future.
 ► By adopting a multisite approach, we can compare 
and contrast experiences across different settings to 
understand which are shared and which are unique 
to a particular context.
 ► The study team are from multiple social and be-
havioural science disciplines meaning that inter-
pretation of the data will be informed by a range of 
social theoretical perspectives.
 ► This study is taking place in a single clinical trial 
and will collect data from individuals in Botswana, 
Uganda and Zimbabwe only which means that the 
results may not be broadly generalisable.
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the conduct of clinical research which would not be 
possible without the willing consent of participants.1 2 
Although antiretroviral therapy (ART) programmes have 
expanded dramatically and AIDS- related deaths have 
reduced, there were still an estimated 940 000 people who 
died from AIDS in 2017.3 In individuals with advanced 
HIV disease the search for superior treatment options for 
fatal opportunistic infections continues.
The AMBITION Trial
The AMBIsome Therapy Induction OptimisatioN (AMBI-
TION) Trial is a phase- III multicentred randomised 
controlled trial recruiting patients with HIV- associated 
cryptococcal meningitis (CM)4 (figure 1). CM is a fungal 
infection of the brain that occurs most frequently in 
severely immunocompromised individuals with a CD4 
count of less than 100 cells/uL.4 There are approxi-
mately 223 000 incident cases of CM globally, with 73% 
of these occurring in sub- Saharan Africa. Annual global 
deaths are estimated at 180 000 and CM is responsible for 
roughly 15% of all AIDS- related deaths.5 The nature of 
the infection means that roughly 40% of patients present 
with confusion6 and some with a significantly reduced 
level of consciousness.
AMBITION is testing a new treatment for CM, a single, 
high dose of a less toxic, liposomal form of amphoter-
icin, and is recruiting 850 participants from eight hospi-
tals across five African countries: Botswana, Malawi, South 
Africa, Uganda and Zimbabwe. The decision- making 
capacity of potential participants is assessed by the clinical 
team who determine if the individual is able to under-
stand the information around the trial, retain that infor-
mation, weigh up the information to make a decision and 
communicate that decision. Patients consent for them-
selves if deemed to have decision- making capacity and if 
they do not, for example, if they are confused or coma-
tose, then a surrogate will do so on their behalf. Partici-
pants are followed up daily during their initial inpatient 
admission (roughly 2 weeks) and then fortnightly as an 
outpatient until they complete the study at 10 weeks. 
Participants have their medical expenses paid for and 
receive transport reimbursements to attend outpatient 
appointments. AMBITION is funded by the European 
and Developing Countries Clinical Trials Partnership 
which brings together researchers from institutions in 
low and middle income countries (LMICs) and Europe.
The AMBITION Trial creates a rich environment for an 
in- depth qualitative study for a number of reasons.
Why participants are motivated to participate in trials
In routine care, mortality with the best standard of care 
treatment for CM is roughly 50% at 10 weeks.7 In recent 
CM trials using the same regimen mortality is roughly 
40%.6 8 It has been observed that even when using the 
same drugs as in routine care, trial participants often 
do better.7 The reasons for this include having a dedi-
cated research team with more time for patients, better 
management of drug- induced toxicities and aggressive 
management of raised intracranial pressure, a common 
and potentially fatal complication of CM, and, inevitably, 
some selection of trial participants. Further widening 
outcomes between routine and trial settings in CM is the 
fact that the most effective drugs may be unavailable, or 
only sporadically available, in routine care. Clinical trials 
are however designed to answer a research question, 
the findings of which it is hoped will later be of benefit 
to a larger population. Some individuals may benefit 
by participating but it is not designed so that everyone 
will.9 Despite this it is not uncommon for research partic-
ipants to expect a personal therapeutic benefit from the 
treatment they receive, including in placebo- controlled 
trials.10 11 Other commonly identified motivators are 
material benefits including free healthcare and trans-
port reimbursements,12–14 and altruism is also a factor.15 
In AMBITION it is fair to expect that all participants will 
benefit, compared with routine care. What is not under-
stood is how this impacts both patients and researchers 
when it comes to motivating to enrol in the trial. Their 
motivation may be rooted in the economic inequality that 
exists between the patient and the research institution 
and which permeates the concept of voluntary partic-
ipation. Voluntariness is understood as an autonomous 
choice without material entanglements and the principle 
of autonomy is often held above others when it comes to 
consenting for a clinical trial.16 Research participants who 
lack agency are therefore subject to ‘structural coercion’ 
whereby their social and economic situation drives them 
into research participation as a means of navigating their 
Figure 1 AMBITION Trial schema. ART: antiretroviral 
therapy, EFA: Early Fungicidal Activity, SAEs: Serious Adverse 
Events, PK/PD: Pharmacokinetics/Pharmacodynamics
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illness and because they may not have any other options 
to get the care they need or desire.17 This is polarised 
when the chance of death is high, such as in CM.
Whom to consent when the patient cannot
In the context of life- threatening illness there are ques-
tions about when to obtain consent and who to obtain it 
from. One option is to commence trial procedures and 
defer consent until the patient is stable, which was accept-
able to 70% of parents in a UK- based emergency paedi-
atric study who felt the process was too much to handle 
in a stressful situation.18 These findings are consistent 
with other studies from the UK.19–21 The Declaration of 
Helsinki states that it is acceptable to recruit someone 
without capacity in best interests22 and it has been argued 
that delaying treatment while waiting for consent risks 
losing out on the potential health benefit of that specific 
emergency treatment and underappreciating the impact 
of emergency treatment due to systematically delayed 
initiation.23 An alternative is therefore to waiver informed 
consent completely, as was the approach in a postpartum 
haemorrhage trial in the UK which found that the 
perceptions of those who gave consent, had a surrogate, 
or waived consent were not dissimilar.11
Regarding who provides the consent, it is typical for 
surrogates to consent on behalf of an unwell patient who 
is confused or comatose. Within CM studies, roughly 40% 
of participants are confused and if they regain capacity 
they reconsent for themselves. Research in high- income 
countries (HICs) has identified that there is generally 
good concordance between surrogates and patients when 
it comes to agreeing to consent to both real life and 
hypothetical trials but that this is reduced in high- risk 
trials.24 25 In LMICs multiple actors are often involved in 
the consent process with partners, parents, older family 
members and community leaders being consulted,10 26 
particularly in the case of severe illness.13 This extends the 
process of gaining consent and can delay recruitment and 
treatment. According to a systematic review of 21 studies 
in Africa, only 47% of participants undergoing informed 
consent understood trial procedures such as randomi-
sation and placebo and only 30% were aware they may 
not experience a therapeutic benefit of participation.27 
Another review found that understanding is significantly 
diminished among those who are critically ill.28 To date 
there have been no in- depth qualitative studies in LMICs 
exploring the process of consent from the perspective of 
an acutely unwell adult or their consenting next of kin.
Participant and next of kin experience
We use the broad term of participant experience to 
encompass the way that an individual navigates through 
the scheduled events of a clinical trial as detailed in the 
protocol. Time is a prominent factor throughout this 
process. An illness occurs at a specific time in some-
one’s life and the entire trial experience is time bound 
and shaped by the protocolised schedule of events. 
A large portion of the ethnographic work exploring 
participant experience of research in LMICs has elicited 
data concerning rumours, most commonly blood stealing, 
which are often dismissed by researchers as expressions of 
ignorance but are interpreted by social scientists as forms 
of popular resistance.29–31 Most ethnographic exploration 
of rumours has been situated in trials of healthy individ-
uals in trials and less commonly in acute, life- threatening 
illness. Lumbar puncture, the procedure used to diag-
nose and treat CM is known to be associated with rumours 
of causing death.32 This has not been extensively studied 
using ethnographic methods but lumbar puncture refusal 
is common and can be fatal.
In the USA there has been an increasing call to assess 
clinical trial participant ‘patient satisfaction’ through the 
use of surveys or interviews which aim to hear the partic-
ipant’s voice and respond by making local improvement 
to the trial.33 In LMICs this approach is less common but 
the concept of ‘good participatory practice’ has been 
developed by the WHO over the years34 and this involves 
elements related to the participant experience.35 No 
ethnographic work has explored these in the context of 
acute illness research in sub- Saharan Africa. Research 
within healthy volunteer studies has found that where 
poor outcomes such as severe disability or death occur, 
this has led to the apportioning of blame or the gener-
ation of rumours about research studies and institu-
tions.29 36 An exploration within AMBITION, where poor 
outcomes are not uncommon, could provide an opportu-
nity to inform and potentially improve the conduct of this 
trial and others in the future.
Researcher experience
Paul Farmer (2002) wrote that ‘researcher and subject 
are living in different worlds’37 and it is commonly 
perceived that there is a mismatch between researcher 
and participant understanding of the research process.29 
Large, randomised controlled trials like AMBITION 
employ a large number of individuals from different 
countries.38 Clinical researchers interact with individ-
uals and their next of kin throughout the trial time-
line14 26 39 40 and are well placed to comment on the 
research process, regulatory approvals and implementa-
tion of a trial. These individuals can therefore provide 
a practical insight and suggestions for improvement.41 
As partners in the research process they can reflect on 
how clinical trials are conceptualised and designed in 
addition to the benefits and shortcomings of transna-
tional partnerships and how we can optimise these rela-
tionships for the benefit of participants.42 International 
researchers often have a broad range of experience 
working in clinical trials and can reflect on the evolution 
of clinical trials over time. As representatives of institu-
tions which are partners (and often the lead) on grant 
applications, they often help to steer the clinical trial 
agenda in the region and are well placed to comment on 
how trials can be improved.
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Aim and objectives
The aim of this study is to explore the experience of 
participants, their next of kin and researchers within the 
AMBITION Trial. By doing this we hope to learn how we 
can improve the trial experience within AMBITION and 
future trials for life- threatening illnesses.
Our specific objectives are:
From the perspectives of the participant, next of kin 
and researcher:
1. To build an understanding of the factors that enhance 
or diminish a clinical trial experience.
From the perspective of the researcher:
2. To compare the individual researcher’s experience of 
the conceptualisation, development, initiation and im-
plementation of a multicentred clinical trial in Africa.
METHODS AND ANALYSIS
Study design
We propose an in- depth qualitative study entitled 
the Lived Experience Of Participants in an African 
RandomiseD trial (LEOPARD). We will adopt a combi-
nation of in- depth interviews (IDIs) and direct obser-
vations to explore the experience of participants, their 
next of kin and researchers within the AMBITION Trial 
(figure 2).
Developing the methodology
The LEOPARD Study was conceived by DSL but the 
methodology was refined with the valuable input of 
social scientists from each of the six AMBITION Trial 
sites. Each social scientist has a particular interest in clin-
ical trials. Over a series of one- on- one discussions and 
group calls the LEOPARD Study evolved. Having devel-
oped a consensus on a methodology it was necessary to 
determine the feasibility of collecting data from six sites. 
Recruitment into the LEOPARD Study will take place in 
Gaborone, Harare and Kampala. The reason for limiting 
data collection to three sites is to enable in- depth data 
collection and to avoid simply skimming the surface by 
diluting down data collection across multiple sites. These 
three sites represent diverse HIV epidemics, healthcare 
systems and political contexts which can be explored 
during data analysis.
Conceptual framework
We will use narrative analysis to explore how the concept 
of time shapes the experience of a life- threatening illness 
and a clinical trial. Drawing on Nancy Munn’s theory of 
temporalisation we will look at how time is experienced 
by different individuals and how the pressure of a life- 
threatening illness impacts the perception of time as well 
as the complex decision to enrol (or not) in a clinical 
trial. By understanding how time and pressure impact the 
meaning and understanding of events at a time of crisis, 
we hope to learn how clinical trials can be better tailored 
to the needs of individuals with life- threatening illnesses. 
Narrative analysis is more commonly adopted by studies 
exploring chronic health conditions but the exploration 
of time is well suited to narrative analysis and a clinical 
trial, which has a clearly defined temporal structure, 
provides a rich setting for story- telling.
IDIs with AMBITION Trial participants
The purpose of the IDIs with AMBITION Trial participants 
is to collect personal accounts of their experience within 
the trial. Individuals who on entry into the AMBITION 
Trial were deemed to have decision- making capacity (ie, 
orientated) and those who were not (ie, disorientated), 
and therefore underwent surrogate consent, will be 
approached. All participants in the LEOPARD Study will 
need to have decision- making capacity to contribute to 
the IDI, meaning that those who lacked decision- making 
capacity at baseline will have clinically improved and 
regained that capacity. We will aim to recruit a maximum 
of 20 participants from each of the three sites, 60 in total, 
with a proposed gender balance of 50%–60% male and 
40%–50% female which is in line with the epidemiology 
of CM at the sites. Consecutively eligible individuals will 
be approached to participate in two IDIs. One will take 
place at least 6 weeks into the 10- week AMBITION Trial 
and the other will take place at least 4 weeks after the 
trial. The reason for this is to allow reflection on the trial 
when one is both within and outside of it. Interviews will 
follow a broad interview schedule and the participant will 
be invited to draw a timeline of the events before, during 
and after the trial (online supplemental file 1). If individ-
uals can only contribute to one IDI, for example due to 
worsening health or unavailability, then the data from the 
first IDI will be retained and analysed.
IDIs with the next of kin of AMBITION Trial participants
The purpose of the IDIs with the next of kin of AMBI-
TION Trial participants is to collect personal accounts 
from individuals who have cared for and made important 
decisions about someone with a life- threatening illness. 
We use the term next of kin as a broad umbrella term to 
include any individual who may be the legal representa-
tive, a caregiver or a surrogate of the participant. This indi-
vidual will have provided consent for the participant to 
enrol into the AMBITION Trial even if they may not have 
been the legally defined next of kin. We will aim to recruit 
a maximum of 15 individuals from each site, 45 in total, 
Figure 2 The Lived Experience Of Participants in an African 
RandomiseD trial (LEOPARD) Study Schema.
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with no specification for gender. Consecutively eligible 
individuals will be approached to participate in a single 
IDI which will take place at least 6 weeks into the AMBI-
TION Trial. At the time of the IDI it will not be necessary 
for the trial participant to have regained decision- making 
capacity and these IDIs do not need to be linked to those 
with participants, although it is anticipated that some will 
be. Interviews will again follow a broad interview schedule 
and the participant will be invited to draw a timeline of 
the events (online supplemental file 2).
IDIs with AMBITION researchers
The purpose of the IDIs with AMBITION researchers is to 
understand their perspectives on how research is designed 
and implemented in Africa. Interviews will take place with 
researchers from each of the research institutions which 
form the AMBITION consortium. At African sites where 
trial participants are being recruited we will approach a 
range of individuals with different roles including senior 
and junior researchers, research doctors and nurses, 
laboratory scientists, pharmacists and study coordinators. 
In addition, individuals who are based at European insti-
tutions will be approached. We will aim for a maximum 
of 12 individuals from each of the three participating 
African sites and 4 from each of the five European sites. 
The maximum number of researcher interviews will be 
56. Individuals will be conveniently sampled and inter-
viewed on a single occasion, following a broad interview 
schedule (online supplemental file 3).
Direct observations of AMBITION researchers
A period of 12 months will be spent conducting ethno-
graphic fieldwork at the African sites. The objective of 
this work is to contextualise the data from IDIs within 
the broader research environment. As the primary focus 
is on improving the trial for participants, observations 
will be largely based in the clinical environment, with 
emphasis placed on observing clinical staff. A total of 
four researchers from each of the three African sites will 
be invited to participate in direct observations. It will be 
made clear that this is not a method designed to appraise 
an individual, but an opportunity to spend a defined 
period of time observing events that take place within the 
research process. Observations will be coupled with brief 
questions to those in close proximity to the activity under 
observation.
Principles of recruitment
Eligible individuals will be approached to enrol in the 
study by a social scientist. In the case of AMBITION Trial 
participants and their next of kin, this will be done in 
the local language by an experienced social scientist at 
that site. In the case of AMBITION researchers this will 
be DSL who is part of the AMBITION Trial Management 
Group in his role as Lead Clinician for the trial. The 
researcher participant will be assured that they are free 
to decline participation and are not being interviewed 
or observed for the purposes of any appraisal or formal 
evaluation of their role within the team. The purpose of 
the researcher interviews and observations is to under-
stand the research process and not to criticise individ-
uals. A reflective approach to the research process will be 
adopted to iteratively refine the data collection methods 
and the communication skills of the social scientists.
Eligible individuals will be provided with a Participant 
Information Sheet and given the opportunity to ask 
questions. If they agree to participate, they will sign an 
Informed Consent Form and will be given the opportu-
nity to withdraw their consent at any time, without giving 
a reason. Interviews will take place in a mutually accept-
able location, be recorded with a digital voice recorder 
and notes will be taken during the interview. Observa-
tions will not be recorded and field notes will be made 
after the period of observation has finished.
It is anticipated that this study may identify aspects of 
the AMBITION Trial that need to be improved. In order 
to ensure this a formal reporting process will be followed. 
Each of the individual social science research assistants 
will report back to DSL. Any urgent issues that relate to 
trial conduct and Good Clinical Practice will be commu-
nicated through the use of direct communication and 
reflective summaries written on the day of data collec-
tion. In addition, weekly meetings will take place between 
the social scientists and DSL to discuss less urgent issues. 
These findings will be communicated either urgently to 
the Trial Management Group or at their weekly meet-
ings, whichever is deemed appropriate. Additional advice 
may be sought from JS who is independent of the AMBI-
TION Trial. Following this process the team will deter-
mine a course of action which may result, for example, in 
additional training of trial staff or modification of study 
procedures. This process is of vital importance to ensure 
that the findings of this study can improve the conduct of 
the ongoing AMBITION Trial. The confidentiality of the 
participant will be maintained throughout this process so 
as not to undermine trust in the study.
Confidentiality
All study documents will be kept on the person of the 
researcher or in a secure, locked location at all times. 
All digital documents will be on a password- protected, 
encrypted computer, backed up regularly and only shared 
with the study team. Names of interviewees will not be 
used at any stage of the data collection process. Prede-
termined identification numbers will be used on data 
collection forms. Audio recordings will not start until the 
interviewee has given consent and will not record their 
name. Pseudonyms will be used throughout. The location 
of researcher participants will be anonymised because the 
small number of eligible participants means that stating 
their location could make it possible to identify them.
Data analysis
Audio recordings will be transcribed verbatim into MS 
Word, translated into English in a separate second step if 
necessary, then exported to NVIVO V.11 for coding and 
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analysis. The first two IDIs from each group of partici-
pants will be analysed and discussed to enable iterative 
refinement of the data collection approach. Similarly, 
regular meetings will be used to review data, refine data 
collection tools and assess for data saturation. We will 
organise the data thematically and analyse it using narra-
tive analysis at the country level by the social science 
team at each site. All data from AMBITION researchers 
will be analysed together using thematic analysis which 
will be performed in six phases: familiarisation with data, 
initial code generation, searching for themes, reviewing 
themes, defining and naming themes, and presenting 
final conclusions. These analyses will then be combined 
in a meta- synthesis of all data, irrespective of location or 
informant, to identify any areas of disconnect and, by 
comparing with country- specific analyses, to assess gener-
alisability of findings.
Patient and public involvement
This protocol has been reviewed by Community Advisory 
Board members, expert patients and HIV activists from 
across the African sites. These individuals and groups 
will continue to be consulted throughout the data collec-
tion process and during the dissemination of research 
findings.
ETHICS AND DISSEMINATION
This study has been approved by the Human 
Resource Development Council, Gaborone (Refer-
ence HPDME:13/18/1); Makerere School of Health 
Sciences Institutional Review Board, Kampala (Refer-
ence: 2019–061); University of Zimbabwe Joint Research 
Ethics Committee, Harare (Reference: 219/19), and 
the London School of Hygiene and Tropical Medicine 
(Reference: 17957). Study findings will be shared with 
research participants from the African and European 
sites, key stakeholders at each research institution and 
ministries of health to help inform the development and 
implementation of future trials. The findings of this study 
will be published in journals and presented at academic 
meetings.
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